SCHEMBL2469181

SCHEMBL2469181

CC(=O)c1c(F)cccc1SC(=O)N(C)C

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.41
POLB P06746 2/20 0.41
CES2 O00748 2/20 0.41
CES1 P23141 2/20 0.41
KMT2A Q03164 2/20 0.38
THRB P10828 1/20 0.36
ATM Q13315 1/20 0.35
GAA P10253 1/20 0.33
LMNA P02545 1/20 0.33
KDM4E B2RXH2 2/20 0.33
PPIA P62937 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10741689 0.82 THRB (0.55) KMT2ATHRBATMKDM4EMEN1
SCHEMBL3338738 0.81 CES2 (0.41) TDP1POLBCES2CES1KMT2A
SCHEMBL167447 0.74 CES2 (0.64) TDP1POLBCES2CES1KMT2A
SCHEMBL16387187 0.73 CA12 (0.50) POLBKMT2AGAALMNAKDM4E
SCHEMBL2467190 0.72 NCEH1 (0.54) KMT2ALMNAKDM4EMEN1
SCHEMBL9725321 0.70 THRB (0.40) THRBGAAKDM4E
SCHEMBL9725322 0.70 THRB (0.40) THRBGAAKDM4E
SCHEMBL13040776 0.70 CES2 (0.52) TDP1POLBCES2CES1KMT2A
SCHEMBL4531060 0.69 MAPT (0.39) TDP1KMT2AATMLMNAMEN1
SCHEMBL8569018 0.69 TDP1 (0.58) TDP1POLBCES2CES1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370422-B1 THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS FIBROGEN INC (US) 2019-06-05 EP disclosed
US-9149476-B2 Thiochromene derivatives as HIF hydroxylase inhibitors FIBROGEN, INC. (US) 2015-10-06 US disclosed
US-20150182528-A1 THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS FIBROGEN, INC. 2015-07-02 US disclosed
US-8927591-B2 Thiochromene derivatives as HIF hydroxylase inhibitors FIBROGEN, INC. (US) 2015-01-06 US disclosed
US-20110305776-A1 THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS FIBROGEN, INC. (US) 2011-12-15 US disclosed
CN-102272117-A Benzothiopyran derivatives as HIF hydroxylase inhibitors 2011-12-07 CN disclosed
EP-2370422-A1 THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS Fibrogen, Inc. (US) 2011-10-05 EP disclosed
WO-2010056767-A1 THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS FIBROGEN, INC. (US) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110305776-A1 THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 TDP1 2259/4885POLB 2030/4885CES2 2668/4885
US-20150182528-A1 THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 TDP1 2259/4885POLB 2030/4885CES2 2668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.